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ABSTRACT Molecular dynamics calculations demonstrated the conformational change in the prion protein due to
Ala1173Val mutation, which is related to Gerstmann-Stra¨ussler-Sheinker disease, one of the familial prion diseases. Three
kinds of model structures of human and mouse prion proteins were examined: (model 1) nuclear magnetic resonance
structures of human prion protein HuPrP (125-228) and mouse prion protein MoPrP (124-224), each having a globular domain
consisting of three -helices and an antiparallel -sheet; (model 2) extra peptides including Ala117 (109-124 in HuPrP and
109-123 in MoPrP) plus the nuclear magnetic resonance structures of model 1; and (model 3) extra peptides including Val117
(109-124 in HuPrP and 109-123 in MoPrP) plus the nuclear magnetic resonance structures of model 1. The results of
molecular dynamics calculations indicated that the globular domains of models 1 and 2 were stable and that the extra peptide
in model 2 tended to form a new -helix. On the other hand, the globular domain of model 3 was unstable, and the -sheet
region increased especially in HuPrP.
INTRODUCTION
Prion diseases are manifested as familial infections or sporadic
diseases, and they cause neurodegenerative disorders such as
kuru, Creutzfeldt-Jacob disease, Gerstmann-Stra¨ussler-Shein-
ker syndrome (GSS), and fatal familial insomnia in humans
and scrapie and bovine spongiform encephalopathy (BSE) in
animals (Prusiner and DeArmond, 1994). These disorders are
thought to be caused by the transformation of a normal prion
protein (PrPC) into an abnormal prion protein (PrPSC), which
accumulates in plaques in the brain (Borchelt et al., 1990). The
replication of PrPSC is thought to occur through interaction
between PrPSC and PrPC with the assistance of a protein X
acting as a chaperon (Telling et al., 1995). PrPC has one
disulfide bridge (Fig. 1) and is anchored to the cell membrane
via a glycosyl phosphatidyl inositol anchor (Stahl et al., 1987,
1992). The important point is that no chemical difference
between PrPC and PrPSC has been identified (Stahl et al.,
1993). However, experiments using circulator dichroism and
Fourier-transform infrared analyses have shown that PrPC has
a low -sheet content (3%) and is sensitive to proteases,
whereas PrPSC has a high -sheet content (30%) and is
protease-resistant (Pan et al., 1993; Safar et al., 1993). Re-
cently, nuclear magnetic resonance (NMR) experiments have
revealed the three-dimensional structures of mouse prion pro-
tein MoPrP (Riek et al., 1996, 1997, 1998), Syrian hamster
prion protein ShPrP (Donne et al., 1997; Liu et al., 1999; James
et al., 1997), bovine prion protein (Garcı´a et al., 2000), and
human prion protein HuPrP (Zahn et al., 2000), all of which
correspond to PrPC. These structural data have indicated that
the N-terminal region (125) is flexible and that the C-termi-
nal region containing the globular domain (125-228) is rigid.
The globular domain consists of three -helices and a short
antiparalell -sheet (Fig. 2).
Most cases of human prion diseases occur spontaneously by
unknown causes. However, familial prion diseases such as
GSS, fatal familial insomnia, and Creutzfeldt-Jacob disease are
related to distinct point mutants within the human gene of PrPC
(PRNP) (Hsiao et al., 1989; Kretzschmar 1993). Point muta-
tions in the PRNP gene are seen in 102, 105, 117, 145, 198,
and 217 in GSS and 178, 200, and 210 in most cases of
Creutzfeldt-Jacob disease. Some mutations related to GSS
occur only in a few families (Tateishi et al., 1990; Hsiao et al.,
1991; Mastrianni et al., 1995), e.g., P102L mutation was de-
tected in more than 30 families, whereas Ala1173Val muta-
tion was detected in only three families (Tranchant et al.,
1997). It is interesting that Ala1173Val mutation requires two
changes in the genetic code to generate an amino acid change.
It is known that Ala1173Val mutation is coupled with Val129,
which is Met/Val heterozygous at codon 129 (Tranchant et al.,
1997). Other experiments on peptides with Ala1173Val mu-
tation have shown that the -sheet region tended to increase
(Brown 2000). In the current work, focusing on the
Ala1173Val mutation, we tried to elucidate the correlation
between Ala1173Val mutation and prion protein (PrP) struc-




Construction of initial structure
MD simulations were performed on three kinds of model structures of
HuPrP and MoPrP. These three model structures were constructed as
follows.
Model 1 was derived from the NMR structures of HuPrP (125-228)
(PDB code (Berman et al., 2000): 1QM2 (Zahn et al., 2000)) and MoPrP
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(124-224) (PDB code (Berman et al., 2000): 1AG2 (Riek et al., 1996)). The
model includes a globular domain, structured part. We called this model a
“control structure.” Model 2 was constructed by adding an extra peptide
chain containing Ala117 (109-124 in HuPrP and 109-123 in MoPrP) to each
of the NMR structures. We called this model a “wild structure.” Model 3
was constructed by adding an extra peptide chain containing Val117 (109-
124 in HuPrP and 109-123 in MoPrP) to each of the NMR structures. We
called this model a “mutant structure.” The extra peptide chains of the wild
and mutant structures were made by quantum chemical calculation (mod-
ified neglect of diatomic overlap parametric method 3
FIGURE 1 Primary structures of HuPrP and MoPrP used in this study. NMR structures of HuPrP and MoPrP consist of residues 125-228 and 124-224
(indicated by  to ). PrP has one disulfide bridge between residues 179 and 214 (indicated asterisks) and is anchored to the cell membrane via a glycosyl
phosphatidyl inositol anchor. This figure includes information on the secondary structure elements (gray regions denote -helices (H1, H2, and H3) and
-sheet (S1 and S2)). Four regions (between S1 and H1, H1 and S2, S2 and H2, and H2 and H3) were named strands 1 to 4. Amino acid numbering is
according to HuPrP.
FIGURE 2 Molecular mechanics potential ener-
gy-minimized structures of the NMR-determined
parts of HuPrP (a) and MoPrP (b).
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approximation) to obtain a locally energy-minimized structure without any
definite formation like an -helix or -sheet, because the N-terminal region
(125) of PrP was unstructured (Fig. 3).
Details of computation
Molecular mechanics potential energy minimizations and MD simulations
were carried out using the program package AMBER5.0 (Case et al.,
1997). The all-atom force field of Cornell et al. (1995) was used in all MD
simulations. The system was solvated with TIP3P water molecules (Jor-
gensen et al., 1983) generated in a rectangular box. The number of solvent
water molecules in each system is shown in Table 1. A periodic boundary
condition was applied, and the pressure was kept constant in the system.
The temperature was kept constant by using Berendsen algorithm (Be-
rendsen et al., 1984) with a coupling time of 0.2 ps. Only bond lengths
involving hydrogen atoms are constrained using the SHAKE method
(Ryckaert et al., 1977). The nonbonded interactions were calculated by a
cutoff method. The distance of the cutoff was 14 Å. The integration time
step of the MD simulations was 1 fs.
The procedure used in our simulations is as follows. First, potential
energy minimizations were performed on each of the initial systems. In
case of wild and mutant structures, after minimizations of only extra
peptide chains and solvent water molecules, the potential energies of the
respective whole systems were minimized. Next, MD simulations were
performed on the energy-minimized systems. In the system of control
structures, after 10-ps MD simulation at 600 K only for solvent water
molecules, the temperatures of the whole systems were gradually increased
by heating to 300 K for 70 ps and then kept at 300 K for the next 2 ns. In
the systems of wild and mutant structures, after 20-ps MD simulations at
600 K only for the extra peptide chains and solvent water molecules (to
remove the arbitrariness for the extra peptide chains of the N-terminal
region), the whole system was gradually heated to 300 K for 70 ps, and
then the temperatures were kept at 300 K for the next 2 ns. The trajectories
at 300 K for 2 ns were considered to be the most probable structure under
physiological conditions and were analyzed in detail.
Secondary structures were analyzed using PROCHECK (Laskowski et
al., 1993), and images of simulated prion proteins were generated using
MOLMOL (Koradi et al., 1996).
Quantum chemical calculations
The models for quantum chemical calculations were constructed by ex-
tracting the extra peptide chains (109-124) from molecular mechanics
potential energy-minimized structures of wild and mutant structures of
HuPrP, and then their C termini were capped with NHCH3. Molecular-
orbital calculations with modified neglect of diatomic overlap parametric
method 3 approximation (Stewart, 1989a,b) were carried out to estimate
the electronic structure. The computational program used is MOPAC
version 6.0 (Stewart and Frank, 1990).
RESULTS
RMSD and residue-based RMSD
Fig. 4(a and b) show root mean square deviations
(RMSDs) of whole parts (109-228) and globular domains
(125-228) of HuPrP models. The RMSD of the control
structure was kept at 3 Å for 2 ns, which indicated that
the globular domain was considerably stable. The
RMSDs of whole parts of wild and mutant structures
increased rapidly within 200 ps and then fluctuated in the
region of 6 to 7 Å. In addition, the RMSD of the globular
domain of the wild structure, as well as that of the control
structure, was maintained at approximately 3 Å for 2 ns,
whereas the RMSD of the globular domain of the mutant
structure gradually increased and fluctuated in the region
of 5 to 6 Å after 1 ns. Fig. 5 a shows the residue-based
RMSDs of HuPrP models. In the control structure, the
residue-based RMSD values were small on the whole
despite some deviation in the N-terminal region (125-
127). In the globular domain of the wild structure, al-
though the values at H1 and the C-terminal side of H3
were somewhat large, the values in other parts were as
small as those in the control structure. The extra peptide
chain (109-124) of the N-terminal region had very large
values (over 10 Å). In the mutant structure, the values at
a strand between S1 and H1 (strand 1), H1, the C-
terminal side of H2, and the C-terminal side of H3 were
clearly larger. We found that the extra peptide chain of
the N-terminal region also had values larger than 10 Å, as
was seen in the wild structure. Analysis of the residue-
based RMSDs indicated that all structures (control, wild,
and mutant) have common characteristics of small values
of S1 and S2.
FIGURE 3 Construction of model structures. The control structure
(NMR-determined structure) is enclosed by a rectangle. The control struc-
ture containing the globular domain consists of three -helices (H1, H2,
and H3) and a short -sheet (S1 and S2). In the wild and mutant structures,
the extra peptide chain is indicated by a broken line.
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Fig. 4 (c and d) show RMSDs of whole parts (109-224)
and globular domains (124-224) of MoPrP models. The
RMSD of the control structure remained at 3 Å for 2 ns,
indicating significant stability of the structure. The RMSDs
of whole parts of the wild and mutant structures increased
rapidly within 200 ps and then fluctuated in the range of 4
to 5 Å and 5 to 8 Å, respectively. Observation of RMSDs in
the globular domain revealed that the RMSD of the wild
structure was similar to that of the control structure and that
its globular domain was completely stabilized. On the other
FIGURE 4 Root-mean-square deviations of
the main chain atoms ((a) RMSD of the whole
part of HuPrP, (b) RMSD of the globular do-
main of HuPrP, (c) RMSD of the whole part of
MoPrP, and (d) RMSD of the globular domain
of MoPrP). Black, blue, and red lines indicate
RMSDs of the control, wild, and mutant struc-
tures, respectively. With regard to the initial
states of MD simulations, the structures of
these globular domains were very similar. The
ordinate is RMSD (Å), and the abscissa is time
(ps).
FIGURE 5 Residue-based root-mean-square deviations (residue-based RMSDs) of the main chain atoms ((a) residue-based RMSD of HuPrP and (b)
residue-based RMSD of MoPrP). RMSDs of the control, wild, and mutant structures are shown by black, blue, and red lines, respectively. The -helices
and -sheet in Fig. 1 are shown as orange and blue bonds on the abscissa, respectively. The ordinate is RMSD (Å), and the abscissa is residue number.
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hand, the RMSD of the mutant structure changed from 4 to
7 Å; thus, its conformation was very different from the
control structure. The residue-based RMSDs of MoPrP
models (Fig. 5 b) indicated that the values of the control
structure were small on the whole despite some deviation in
the N-terminal region (125-127) and H1. In the globular
domain of the wild structure, although the C-terminal side
of H3 had large values, the values of other parts were as
small as those of the control structure. The extra peptide
chain (109-123) of the N-terminal region had large values
(10–14 Å). In the mutant structure, the values at H1, a
strand between S2 and H2 (strand 3), a strand between H2
and H3 (strand 4), and the C-terminal side of H3 were far
larger than those in the control and wild structures. The
extra peptide chain of the N-terminal region also had very
large values (10–18 Å) as was seen in the wild structure of
MoPrP. The values of S1 and S2 were small in all structures
(control, wild, and mutant), as consistently seen in those of
HuPrP models.
These data revealed that the large RMSD of the whole
part of the wild structure arose not from structural change in
the globular domain but from structural change in the extra
peptide chain of the N-terminal region. On the other hand,
the large RMSD of the whole part of the mutant structure
was due not only to the structural change in the extra
peptide chain of the N-terminal region but also to the
dramatic structural change in the globular domain.
MD simulation structures
HuPrP
The average control structure is shown in Fig. 6 a. This
figure indicates that the globular domain containing three
-helices and a short antiparallel -sheet is stably main-
tained. The secondary structures of the control structure
were similar to those of the NMR structure of HuPrP,
although the -helix at the C-terminal side of H3 was
slightly transformed into a 310-helix after 1.5 ns (Fig. 7 a).
Moreover, the contact map (Fig. 8 a) indicated that the final
structure, the MD simulation structure at 2 ns, matched the
initial structure of MD simulation. Accordingly, the control
structure was concluded to be stably maintained for 2 ns of
MD simulation.
A noticeable feature of the average wild structure was
that the extra peptide chain in the N-terminal region, which
was a random strand at initial state of MD simulation,
formed a new -helix (H0) (Fig. 6 b). This extra peptide
chain began to form - and 310-helices at700 ps, and then
the new -helix, H0, was almost completed within the extra
peptide chain at 2 ns.
This observation was supported by the finding that the
sum of - and 310-helix contents in the globular domain was
less than those of the whole structure by 10 amino acid
residues (Table 2).
FIGURE 6 Average structures of HuPrP
models ((a) control structure, (b) wild struc-
ture, and (c) mutant structure). These struc-
tures were obtained from the final 1-ns MD
simulations.
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The average structure (Fig. 6 b) showed that H1 was
deformed and somewhat unstable. The instability of H1
would be a cause to form the hydrogen bonds of Tyr150-
OH–Arg136O and Tyr150OH–Pro137O, which were not ob-
served in the initial structure. Parts other than H1 in the
globular domain were similar to those of the initial struc-
ture. Analysis of the secondary structure (Fig. 7 a) also
indicated that H1 changed from an -helix to a 310-helix and
then become unstable. Thus, the decrease in the -helix
content and the increase in the 310-helix content in the wild
structure were mainly due to a structural change in H1
(Table 2). This mobility of H1 is supported by NMR ex-
periment (Garcı´a et al., 2000). The H2, H3, and short
antiparallel -sheet in the globular domain were stably
maintained for 2 ns in the same manner as the control
structure (Fig. 7 a). Table 3 shows positions of secondary
structure elements. It is obvious from this table that the
globular domain of the wild structure was similar to that of
the control structure, although a new -helix (H0), which
was not observed in the control and mutant structures, was
generated. It was seen in the contact map (Fig. 8 b) that H0
was close to H2. Analyses of RMSD and secondary struc-
tures indicated that the interaction between H0 and H2 did
not influence the structure of the globular domain.
FIGURE 7 Secondary structure as a function of simulation time ((a) HuPrP and (b) MoPrP). Top figures show control structures, middle figures show
wild structures, and bottom figures show mutant structures. The -helix is shown in a red box, 310-helix in a yellow box, -sheet in a blue box, -bridge
in a green box, and turn in a black box.
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An interesting finding in the MD simulation of the mutant
structure was that the original antiparallel -sheet had been
extended. The average structure (Fig. 6 c) clearly indicated
the extension of the -sheet. Analysis of the secondary
structures (Fig. 7 a; Table 2) indicated that the extension of
the -sheet occurred from 1 ns and that the -sheet content
(8.12 residues) was approximately two-times greater than
those of the control and wild structures (3.67 and 4.65
residues, respectively). The H1 region, which is between S1
and S2, was deformed with this extension of the original
-sheet, and, as a consequence, the central part of H1
collapsed (Fig. 6 c; Table 3). The collapse of H1 gave rise
to the disappearance of even the two hydrogen bonds
(Tyr150OH–Arg136O and Tyr150OH–Pro137O) that were
formed in the MD simulation of the wild structure.
We speculate that the mechanism of the extension of
the -sheet in MD simulation of the mutant structure is as
follows. The main reason for the extension is the behav-
ior of the extra peptide chain in the N-terminal region
containing Val117. This extra peptide chain does not form
a secondary structure, such as an -helix, due to the
effect of Val117 and it sways flexibly (Figs. 6 c and 7 a).
Its motion induces a structural change in strand 1, which
is linked to S1, and then strand 1 approaches strand 2,
which is located between H1 and S2. As a result, exten-
sion of the -sheet occurs. In addition, residues 120-127
in the extra peptide chain interacted with the C-terminal
side of H3 (Fig. 8 c), so that the -helix of H3 was
unlaced and was divided into two parts (Table 3). On the
other hand, H2 was not directly affected by the extra
peptide chain, and it was stably maintained (Fig. 7 a).
Thus, the large RMSD values of the globular domain
(Fig. 4 b) arise from structural changes in strand1, H1,
and H3.
FIGURE 8 Contact map ((a) control model of
HuPrP; (b) wild model of HuPrP; (c) mutant
model of HuPrP; (d) control model of MoPrP;
(e) wild model of MoPrP; and (f) mutant model
of MoPrP). Left upper and right lower triangles
in each graph indicate the initial and final struc-
tures of MD simulation, respectively. The dis-
tance within 5 Å is shown in red, the distance 5
to 8 Å in blue, and the distance 8 to 11 Å by
open squares.
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MoPrP
The average structure of the control model (Fig. 9 a) shows
that the globular domain was stably maintained, although
some deformation of the H3 region was seen. A contact map
(Fig. 8 d) also revealed that the initial and final structures of
MD simulation were the same except for some slight dif-
ferences. The data of secondary structures (Fig. 7 b) indi-
cated that H2 was stable, whereas the 310-helix contents of
H1 and H3 increased compared with those of HuPrP, sug-
gesting the instabilities of H1 and H3 that would have arisen
due to the difference between the primary structures of
HuPrP and MoPrP. In addition, it was noted that the -sheet
content increased from 1.5 ns (Fig. 7 b); thereby, its content
(6.20 amino acid residues) was more than those of wild and
mutant structures of MoPrP and the control and wild struc-
tures of HuPrP (Table 2).
In the case of the wild structure, the extra peptide chain
(residues 112-117) of the N-terminal region formed a new
-helix (H0) in the same manner as that of HuPrP (Figs. 9
b and 7 b; Table 3). This extra peptide chain began to form
- and 310-helices from approximately 800 ps in the MD
simulation. In addition, residues 123-124 of the extra pep-
tide chain formed a -bridge with S1, and synchronously
the -sheet content, which consisted of S1 and S2, de-
creased. A contact map (Fig. 8 e) indicated that residues
123-124 were close to the -sheet (S1 and S2) but that the
approach of these residues to the -sheet did not affect the
conformation of the globular domain.
In MD simulation of the mutant structure, we observed
that the relative positions among three -helices (H1, H2,
and H3) of the globular domain were very different from
those in the control and wild structures (Fig. 9 c). H1, in
particular, moved a long distance from its initial position
(Fig. 5 b), and this movement would have induced the
extension of the distances of H1-H3 (Fig. 8 f). The analysis
of the secondary structure (Fig. 7 b) clearly showed that the
extra peptide chain formed a -bridge with S1 in the same
manner as that in the wild structure of MoPrP but that was
largely unstructured and did not form an -helix. Moreover,
a contact map (Fig. 8 f) indicated that the residues 115-117
of the extra peptide chain interacted with the C-terminal
side of H3. We speculate that this interaction and the high
instability of H1 caused the large RMSD values of the
globular domain.
Electric structure
The electronic states of the extra peptide chains (109-124)
in the wild and mutant structures were analyzed using
semiempirical molecular orbital calculations (modified ne-
glect of diatomic overlap parametric method 3). Fig. 10
shows the isosurface for an electron density of 0.0003
e/Bohr3 in the high occupied molecular orbital (HOMO).
From the lowest unoccupied molecular orbital (LUMO) to
the third LUMO, there was no difference between the elec-
tronic structures of the wild and mutant models. Notable
differences were also not seen between these models from
the fourth LUMO to the tenth LUMO (data not shown). On
the other hand, we observed a clear difference between the
electric structures at the third HOMO, although no differ-
ences were seen in the cases of HOMO and the second
HOMO (Fig. 10). At the third HOMO, the mutant model
only has the electron distribution in peptide chain 119-122,












Control 104 7.56 55.13 0.05 3.67 1.82 7.98
(103) (11.34) (44.25) (0.14) (6.20) (1.78) (21.35)
104* 15.31* 47.14* 0.00* 4.65* 1.86* 10.32*
(103)* (8.79)* (53.75)* (1.55)* (1.74)* (0.79)* (13.67)*
Wild 120 21.36 50.20 0.00 4.65 1.86 15.19
(118) (9.78) (58.04) (2.05) (2.74) (1.22) (16.80)
Mutant 104* 12.45* 46.31* 0.01* 8.12* 1.78* 12.18*
(103)* (12.79)* (50.04)* (1.65)* (3.94)* (1.92)* (11.08)*
120 13.55 46.31 0.01 8.12 1.78 15.07
(118) (14.92) (50.06) (1.88) (3.94) (1.92) (15.31)
Numbers are the average numbers of amino acids for the final 1-ns MD
simulation.
The data for HuPrP are shown without parentheses, and the data for MoPrP
are shown in parentheses.
*Secondary structure content of the globular domain.
TABLE 3 Positions of secondary structure elements for
NMR experiments and MD simulation structures of HuPrP and
MoPrP models
NMR
experiment Control Wild Mutant
S1 128–131 129–130 129–130 129–133
(128–133) (129–132) (128–129) (128–130)
S2 161–164 162–163 162–163 160–164
(161–164) (160–163) (162–163) (162–163)
H1 144–154 145–157 145–157 145–150,
152–157†
(144–153) (145–157) (143–157) (143–157)
H2 173–194 171–195 171–195 171–195
(172–194) (175–194) (172–195) (172–192)
H3 200–228 200–228 200–228 201–219,
222–228†
(200–224) (199–223) (199–226) (200–226)
S0* – – – –
(–) (–) (–) (124)
H0* – – 112–124 –
(–) (–) (112–117) (–)
The data for HuPrP are shown without parentheses, and the data for MoPrP
are shown in parentheses. Positions of H0–H3 correspond to residues
forming -helix or 310-helix and those of S0–S2 correspond to residues
forming -sheet or -bridge.
*S0 and H0 are additional -sheet and -helix in residues 104–124,
respectively.
†-Helix is split.
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and it has higher reactivity at residues 119-122 by
Ala1173Val mutation. We speculate that this high reactiv-
ity is a driving force for the motion of the extra peptide
chain containing Val117. Such high reactivity would be
related to the interaction of the extra peptide chain in the
N-terminal region with the globular domain in MD simula-
tion of the mutant structure.
DISCUSSION
MD simulations of the control, wild, and mutant structures
of HuPrP and MoPrP showed that they have some common
features. The most remarkable common feature is that the
globular domain of the wild structure was stable and re-
tained the same conformation as that of the control struc-
ture, whereas that of mutant structure was unstable. The
reason for this is as follows. The extra peptide chain in the
wild structure formed an -helix and was maintained stably,
and it therefore did not affect the structure of the globular
domain. The extra peptide chain in the mutant structure
containing Val117, however, formed few secondary struc-
tures, such as an -helix and -sheet, and it could therefore
move flexibly to interact with the globular domain.
MD simulation showed that the control structures of
HuPrP and MoPrP were similar to the respective NMR
structures, although H1 and H3 were somewhat unstable in
MoPrP. Thus, the MD simulations revealed that globular
domains, which were determined by experiments of NMR,
were stably maintained. MD simulations of the wild struc-
tures of HuPrP and MoPrP indicated that the extra peptide
chain in the N-terminal region tended to form an -helix.
Gready and co-workers reported the results of MD simula-
tions using HuPrP that was built based on ShPrP (Zuegg and
Gready, 1999). Their MD simulations (800 ps) also indi-
cated that - and 310-helices were formed in 110-120 resi-
dues. Therefore, simulations in our studies and those in their
study show similar tendencies. Accordingly, at least theo-
retical simulations intimated a potential of 110-120 residues
to form an -helix. The experimental data of NMR showed
that the N-terminal region except for the globular domain
was flexible and had a disordered structure (Riek et al.,
1997; Zahn et al., 2000). To examine the reason for the
above in compatibility between simulations and experi-
ments, further study should be needed on the conformation
of the 109-124 part of wild structure. MD simulations of the
mutant structure provided us very important information.
The results for HuPrP indicated that the original short
antiparallel -sheet was extended greatly. This phenomenon
would be the first step in the mechanism of structural
change from PrPC to PrPSC by Ala1173Val mutation. That
is, the first step in the PrPC3PrPSC mechanism is as fol-
lows. The structural change in strand 1 between S1 and H1
FIGURE 9 Average structures of MoPrP
models ((a) control structure, (b) wild struc-
ture, and (c) mutant structure). These struc-
tures were obtained from the final 1-ns MD
simulations.
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FIGURE 10 Electron distributions in HOMO, second HOMO, and third HOMO. Isosurfaces for electron density of 0.0003 e/Bohr3 are shown in dots.
The figures on the left are wild models, and the figures on the right are mutant models.
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occurred due to a flexible motion of the N-terminal region
(109-124), and then strand 1 approached strand 2 between
H1 and S2. Consequently, the original -sheet was ex-
tended. Accompanying this extension, a deformation of the
globular domain, involving collapse of H1, occurred. It is
known that H1 is very hydrophilic and that other parts of the
globular domain are very hydrophobic, and interaction be-
tween them is therefore weak (Morrissey and Shakhnovich,
1999). Experiments performed by Korth et al. (1997) using
a monoclonal antibody showed that structures of H1 in PrPC
and PrPSC were different, which is compatible with our
result in terms of the deformation of H1 in mutant structure.
In addition, experiments performed by Hanan et al. (2001)
using a monoclonal antibody showed that the peptide chain
106-126 played an important role in the structural change of
PrPC. These results supported our computational results
regarding the dynamic motion of H1 and the peptide chain
(109-124). After the above-mentioned structural change, the
-sheet would be extended far more in accordance with the
completion of PrPSC. Because an experiment using peptide
106-126 showed that Ala1173Val mutation increased the
-sheet structure (Brown 2000), it is thought that the extra
peptide chain containing Val117 is involved in the extension
of the -sheet. A study on point mutations of inherited
diseases involving HuPrP revealed that not all mutations
reduced the thermal stabilities of the globular domain (Li-
emann and Glockshuber, 1999). However, the current mo-
lecular dynamics study demonstrated that thermal stability
of the globular domain is decreased due to the Ala1173Val
mutation.
Although these simulations have not yet perfectly been
finished in the whole process of structural change from PrPC
into PrPSC, rapid increase of computational resource, such
as molecular dynamics machine (Narumi et al., 2001), will
enable us to realize it.
CONCLUSIONS
We provide the following conclusion from this study.
Ala1173Val mutation deforms the structures of the globular
domains on HuPrP and MoPrP. Especially in HuPrP con-
taining Val117, the extension of the -sheet and the collapse
of H1 occur. PrPC containing Ala117 tended to form -helix
in the extra peptide chain (109-124 in HuPrP and 109-123 in
MoPrP). The extra peptide chain 119-122) containing
Val117 takes high electron distribution in some frontier
molecular orbitals and had a high reactivity. These would be
the driving force for the flexible motion of the N-terminal
region of the mutant structure.
This work was supported by the super computer VPP700 in RIKEN. The
computations were also carried out by the DRIA System at the Graduate
School of Pharmaceutical Sciences, Chiba University.
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